Short description
MetaStat develops diagnostic technologies and therapeutics for the early detection and treatment of systemic metastasis.
Description
MetaStat is focused on developing and commercializing novel diagnostic technologies and therapeutics for the early and reliable prediction and treatment of systemic metastasis, a cancer that spreads from a primary tumor through the bloodstream to other areas of the body. The company also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.
Last funding
Nopepepe
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Montclair, New Jersey, United States, North America
Founded on
January 1, 2010
Exited on
March 23, 2015
Went public on
March 23, 2015
Delisted on
July 16, 2018
Stock symbol
MTST
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$34056 - 789030
Sign in for full access
Founders
Warren C. Lau